{"id":1201,"date":"2026-09-27T03:22:00","date_gmt":"2026-09-27T07:22:00","guid":{"rendered":"https:\/\/drugchatter.com\/insights\/?p=1201"},"modified":"2026-09-21T17:30:58","modified_gmt":"2026-09-21T21:30:58","slug":"the-competitive-landscape-for-ai-search-visibility-in-pharma-whos-actually-building-what","status":"publish","type":"post","link":"https:\/\/drugchatter.com\/insights\/the-competitive-landscape-for-ai-search-visibility-in-pharma-whos-actually-building-what\/","title":{"rendered":"The Competitive Landscape for AI Search Visibility in Pharma: Who’s Actually Building What"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

Real Chemistry billed HealthGEO, launched on August 21, 2025, as the industry’s first healthcare-specific generative engine optimization (GEO) intelligence platform [1][2]. Eleven months later, the company folded it into a broader AI ecosystem called Real Chemistry ANATOMI [2]. In that same window, Profound raised four funding rounds worth more than $335 million and reached a $1.8 billion valuation [3][4][5], while a widely cited “pharma-native” competitor sometimes named alongside it has no independently verifiable funding history, customer list, or founding team in public records as of this writing.<\/p>\n\n\n\n

That gap between market-map marketing and market reality is the actual story of AI search visibility in pharma right now. The category is real and growing. The vendor pool serving it is smaller, messier, and more concentrated in general-purpose tools than most buyer’s-guide content suggests.<\/p>\n\n\n\n

The Short Answer<\/strong><\/h2>\n\n\n\n

As of September 2026, pharma-specific AI-visibility monitoring is served by a small number of vertical entrants \u2014 DrugChatter and Real Chemistry’s HealthGEO\/ANATOMI chief among the verifiable ones \u2014 plus general-purpose GEO platforms (Profound, Scrunch AI, Peec AI, Semrush’s AI Visibility Toolkit, Ahrefs Brand Radar) that pharma marketing and medical affairs teams have adopted as a stopgap. A third tier of established pharma data and CRM vendors \u2014 Veeva, IQVIA, AlphaSense\/Cortellis \u2014 has added generative AI to existing products, but that AI is built for internal research and commercial engagement, not for monitoring what ChatGPT or Gemini tells a patient or prescriber about a drug.<\/p>\n\n\n\n

Why AI Search Visibility Is a Different Problem in Pharma<\/strong><\/h2>\n\n\n\n

A retailer that gets misdescribed by ChatGPT loses a sale. A pharmaceutical company that gets misdescribed risks a labeling discrepancy, an off-label implication, or a safety-information gap reaching a patient or prescriber directly, outside any promotional review process. Worldcom Public Relations Group’s fifth annual Healthcare Monitor report, published in July 2026, made GEO visibility one of its core scoring components for the first time, alongside website performance and audience targeting, when it evaluated ten global pharmaceutical companies including Pfizer, Roche, Novartis, and Merck [6].<\/p>\n\n\n\n

That distinction \u2014 commercial visibility risk versus regulated-content risk \u2014 is the organizing fact behind every vendor decision in this piece. A generic AI-visibility tool can tell a brand team that ChatGPT mentioned a competitor’s drug first. It generally cannot tell a pharmacovigilance team that ChatGPT described a contraindication incorrectly, because it has no FDA label, EMA SmPC, or REMS data to check the answer against.<\/p>\n\n\n\n

The Market Map: Three Tiers<\/strong><\/h2>\n\n\n\n
Tier<\/th>What it optimizes for<\/th>Representative vendors<\/th>Built against a drug label?<\/th><\/tr><\/thead>
Pharma-native AI monitoring<\/td>Label alignment, clinical accuracy, audience-specific briefings<\/td>DrugChatter, Real Chemistry HealthGEO\/ANATOMI<\/td>Yes<\/td><\/tr>
General-purpose GEO \/ AI visibility<\/td>Share of voice, citation rate, competitive mention tracking<\/td>Profound, Scrunch AI, Peec AI, Semrush AI Visibility Toolkit, Ahrefs Brand Radar<\/td>No<\/td><\/tr>
Adjacent legacy pharma intelligence<\/td>Internal competitive research, CRM-driven field engagement<\/td>Veeva, IQVIA, AlphaSense\/Cortellis<\/td>Indirectly, via internal data, not external AI answers<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Tier 1: Pharma-Native AI Monitoring<\/strong><\/h2>\n\n\n\n

This is the tier the market genuinely needs and the one with the fewest independently documented entrants.<\/p>\n\n\n\n

DrugChatter<\/strong><\/h3>\n\n\n\n

DrugChatter runs weekly automated query cycles across multiple LLM vendors against a defined set of brand and therapeutic-area prompts, then compares the resulting answers against FDA labeling for accuracy and generates separate briefings for different internal audiences \u2014 executive, marketing, pharmacovigilance, medical affairs, and regulatory affairs, among others \u2014 rather than a single generic visibility report. That audience-segmented structure is the practical difference between a marketing dashboard and a tool a PV or regulatory team can actually act on: a share-of-voice number tells a brand manager something, but it tells a pharmacovigilance reviewer nothing about whether a chatbot just omitted a boxed warning.<\/p>\n\n\n\n

Real Chemistry HealthGEO \/ ANATOMI<\/strong><\/h3>\n\n\n\n

Real Chemistry, a healthcare-focused marketing and communications agency with more than 2,000 employees, launched HealthGEO on August 21, 2025 as an AI search product built specifically for life sciences communicators [1]. The company described it as helping clients see the outputs, biases, gaps, and potential misinformation that LLMs like ChatGPT and Gemini generate about their science and brands [1]. In July 2026, coinciding with Real Chemistry’s 25th anniversary, the company relaunched HealthGEO as part of a larger AI ecosystem called Real Chemistry ANATOMI, describing HealthGEO’s next-generation version as the industry’s first healthcare-specific GEO intelligence platform [2]. ANATOMI also folds in publications-workflow and FDA compliance-risk-evaluation tooling, positioning it closer to an agency-embedded AI suite than a standalone SaaS subscription [2].<\/p>\n\n\n\n

The Names That Don’t Hold Up to Scrutiny<\/strong><\/h3>\n\n\n\n

Vendor-comparison content across the GEO category frequently places AthenaHQ in a “pharma-native” bucket alongside DrugChatter. That classification does not survive a look at the company itself. AthenaHQ is a Y Combinator-backed generative engine optimization startup founded by former Google Search and DeepMind engineers, and its own marketing, pricing pages, and customer positioning describe general B2B brand monitoring across ChatGPT, Perplexity, Gemini, and other engines \u2014 with no disclosed pharmaceutical vertical, healthcare compliance feature, or life-sciences customer base [7][8]. It belongs in the general-purpose tier below, not this one.<\/p>\n\n\n\n

A second name that circulates in pharma AI-monitoring market maps, sometimes rendered as Inpharmativ, does not turn up an independently verifiable company profile, funding record, or founding team in public business databases, press coverage, or company-registry sources as of this writing. That does not mean no such company exists \u2014 pre-seed and stealth-stage vendors routinely operate below the threshold of press coverage \u2014 but it does mean any specific claim about its capabilities, funding, or customers should be treated as unverified until the vendor publishes primary-source evidence for it.<\/p>\n\n\n\n

The practical finding for brand and CI teams: the pharma-native tier of this market is thinner than comparison articles suggest. Two verifiable vendors, not three or four, currently build AI-visibility monitoring around a drug label rather than a generic brand mention.<\/p>\n\n\n\n

Tier 2: General-Purpose GEO Platforms Pharma Teams Use as a Stopgap<\/strong><\/h2>\n\n\n\n

These platforms were not built for regulated industries, but their model coverage, pricing, and self-serve onboarding make them the default choice for pharma marketing and digital teams that need an AI-visibility baseline before a pharma-native tool is budgeted or approved.<\/p>\n\n\n\n

Profound<\/strong><\/h3>\n\n\n\n

Profound is the best-funded company in the category. Founded in New York in 2024 by James Cadwallader and Dylan Babbs, it raised a $3.5 million seed round, a $20 million Series A led by Kleiner Perkins, a $35 million Series B led by Sequoia Capital in August 2025 that brought total funding to $58.5 million [9], a $96 million Series C led by Lightspeed Venture Partners in February 2026 that pushed total funding past $155 million [4], and a $180 million Series D co-led by Sequoia and Kleiner Perkins that valued the company at $1.8 billion [5]. Its platform tracks brand mentions across engines including ChatGPT, Gemini, Perplexity, Claude, Grok, and Google’s AI Overviews and AI Mode, and adds content-generation and marketing-agent features on top of monitoring [10]. Customers disclosed in company and press materials include Ramp, Indeed, MongoDB, DocuSign, Target, and Walmart [9][5] \u2014 a roster with no disclosed pharmaceutical or life-sciences brand.<\/p>\n\n\n\n

Scrunch AI<\/strong><\/h3>\n\n\n\n

Scrunch, headquartered in Salt Lake City and led by CEO Chris Andrew, has raised roughly $19 million across two rounds from Decibel, Mayfield, and Homebrew [11]. Its differentiator is the Agent Experience Platform (AXP), a middleware layer that detects AI-crawler traffic and serves it structured, machine-readable content without changing what human visitors see [12][13]. That is a genuinely different capability from pure monitoring: Scrunch tries to change what AI systems retrieve, not just report on what they say. Disclosed clients span consumer and enterprise brands such as Lenovo, Dell, SKIMS, and Penn State University, with pricing starting near $250 to $300 a month for the core enterprise tier [11][13].<\/p>\n\n\n\n

Peec AI<\/strong><\/h3>\n\n\n\n

Peec AI launched in February 2025 out of Berlin and positions itself as a fast, low-friction entry point into AI-search monitoring rather than a full optimization suite [13][14]. Independent funding figures for Peec AI vary by source; a comparison page published by Scrunch AI lists Peec’s total raised at $29 million [11], while entry pricing across multiple vendor-comparison sources sits around $95 to $99 a month [14][15].<\/p>\n\n\n\n

Semrush AI Visibility Toolkit<\/strong><\/h3>\n\n\n\n

Semrush launched its AI Visibility Toolkit as a standalone product in early 2025 and folded it into the broader Semrush One bundle in October 2025 [16]. It tracks brand presence across ChatGPT, Gemini, Perplexity, and Google’s AI Mode and AI Overviews, and pairs an AI Visibility Score with a Brand Performance Analysis feature that flags which sources AI systems cite and whether the resulting brand mentions read positive, neutral, or negative [16]. It also includes an AI Readiness Audit checking more than two dozen technical and structural factors that can block AI systems from properly reading a site [16].<\/p>\n\n\n\n

Ahrefs Brand Radar<\/strong><\/h3>\n\n\n\n

Ahrefs built Brand Radar directly into its existing SEO platform, drawing on a prompt database independent sources put at well over 100 million real search-derived prompts, rather than synthetic test queries [17][18]. It tracks visibility across engines including ChatGPT, Google AI Overviews and AI Mode, Perplexity, Gemini, and Copilot, and extends citation tracking into YouTube, TikTok, and Reddit alongside the conventional web [17][18]. Because it lives inside an existing Ahrefs subscription, pricing is additive rather than standalone, with reported per-platform pricing near $99 to $129 a month and full-bundle pricing cited as high as $699 a month in some comparisons [15][18].<\/p>\n\n\n\n

How the general-purpose tier compares<\/h4>\n\n\n\n
Platform<\/th>Founded \/ launched<\/th>Disclosed funding<\/th>Distinctive capability<\/th><\/tr><\/thead>
Profound<\/td>2024, New York<\/td>$335M+ across four rounds [3][4][5][9]<\/td>Broadest engine coverage plus content and agent tooling [10]<\/td><\/tr>
Scrunch AI<\/td>2023\u201324, Salt Lake City<\/td>~$19M [11]<\/td>Agent Experience Platform serves AI crawlers directly [12]<\/td><\/tr>
Peec AI<\/td>Feb. 2025, Berlin<\/td>Disputed; one source cites $29M [11]<\/td>Fast, low-cost entry-level monitoring [13]<\/td><\/tr>
Semrush AI Visibility Toolkit<\/td>Early 2025 (standalone); Oct. 2025 (bundled)<\/td>N\/A \u2014 Semrush is public<\/td>AI Readiness Audit and sentiment-framed Brand Performance Analysis [16]<\/td><\/tr>
Ahrefs Brand Radar<\/td>2025, bundled into Ahrefs<\/td>N\/A \u2014 Ahrefs is privately profitable<\/td>Very large real-prompt database; extends to social platforms [17]<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Why General-Purpose Tools Fall Short for Regulated Brands<\/strong><\/h3>\n\n\n\n

None of the five platforms above check an AI-generated answer against an FDA label, a REMS requirement, or an EMA SmPC. None distinguishes an on-label claim from an off-label implication. That is not a criticism of the products \u2014 they were built for retail, SaaS, and consumer brands, where the relevant question is “did the model mention us,” not “did the model describe our black-box warning correctly.” For a pharma brand team doing a first-pass visibility check, or for a digital marketing group with no budget yet for a pharma-specific tool, these platforms are a reasonable stopgap. For medical affairs, regulatory, or pharmacovigilance functions, they answer the wrong question.<\/p>\n\n\n\n

Tier 3: Adjacent Legacy Vendors Adding AI Features<\/strong><\/h2>\n\n\n\n

Veeva, IQVIA, and AlphaSense\/Cortellis are each investing heavily in generative AI. None of the three, based on their own public product descriptions, is building a tool to monitor how ChatGPT or Gemini describe a specific drug to an outside user.<\/p>\n\n\n\n

Veeva<\/strong><\/h3>\n\n\n\n

Veeva’s AI investment centers on Vault CRM and an initiative the company calls Veeva.ai, aimed at giving field teams agentic tools inside the CRM they already use. Throughout 2026, Veeva announced a run of global Vault CRM commitments from major pharmaceutical companies, including Eli Lilly, Gilead Sciences, Bristol Myers Squibb, Regeneron, Biogen, and Teva, alongside an earlier expanded partnership with Roche [19][20][21]. Veeva frames the resulting AI layer around what it calls Commercial Evidence \u2014 structured insight captured from field engagement, such as which objections a prescriber actually raised \u2014 with Veeva citing that 65% of field calls surface an actionable treatment barrier [19]. On its Q1 2026 earnings call, Veeva said its embedded AI initiative was on track to deliver its first CRM agent by year-end, with a goal of lifting life-sciences commercial efficiency by roughly 15% by 2030 [22]. This is customer-engagement AI operating on a company’s own CRM data. It has no connection to monitoring what a public chatbot tells a patient.<\/p>\n\n\n\n

IQVIA<\/strong><\/h3>\n\n\n\n

Independent research firm Everest Group named IQVIA a generative AI “front-runner” for life sciences in an April 2025 report, citing its integration of generative AI into clinical trial design, provider-engagement analytics, and market-access insight generation under what IQVIA brands as Healthcare-grade AI [23][24]. IQVIA also offers a Social Media Intelligence product that gives brand and digital marketing teams a consolidated competitive-benchmarking dashboard, combining AI analysis with human validation [25]. That product tracks social and digital channels, not generative AI chatbot answers specifically, and IQVIA has not published a dedicated AI-chatbot monitoring product as of this writing.<\/p>\n\n\n\n

AlphaSense \/ Cortellis<\/strong><\/h3>\n\n\n\n

AlphaSense, a market-intelligence platform, launched Generative Search and Generative Grid in March 2025, giving users natural-language access to more than 450 million searchable documents, including ClinicalTrials.gov, FDA, EMA, and PubMed content [26]. Cortellis, the companion pharma-specific dataset AlphaSense positions alongside it, supplies structured, Ph.D.-curated data on drug pipelines, clinical trials, regulatory actions, and patent and generics timelines, but AlphaSense’s own comparison page notes that Cortellis on its own lacks the generative AI search layer needed to synthesize unstructured content [27]. Together, the pairing is built for competitive-intelligence and business-development research \u2014 querying what is known about a competitor’s pipeline \u2014 not for sampling what a public AI assistant currently says about an approved drug.<\/p>\n\n\n\n

An Original Taxonomy: Three Different Jobs Wearing the Same “AI” Label<\/strong><\/h2>\n\n\n\n

Reading across all three tiers, the vendors sort cleanly into three distinct jobs that the industry currently blurs together under one “AI in pharma” umbrella:<\/p>\n\n\n\n

    \n
  • External answer monitoring.<\/strong> Sampling what public AI systems say to an outside user and checking it against an authoritative source. Only the Tier 1 vendors do this against a drug label specifically; the Tier 2 vendors do a version of it against brand mentions generally.<\/li>\n\n\n\n
  • Answer shaping.<\/strong> Trying to influence what AI systems retrieve and cite, either through structured content (most Tier 2 platforms’ recommendations) or through crawler-facing infrastructure (Scrunch’s AXP specifically).<\/li>\n\n\n\n
  • Internal synthesis.<\/strong> Using generative AI to search, summarize, or act on a company’s own data \u2014 CRM records, licensed market-intelligence datasets, regulatory filings. This is what Veeva, IQVIA, and AlphaSense\/Cortellis are building, and it does not touch what a public chatbot tells anyone outside the company.<\/li>\n<\/ul>\n\n\n\n

    A brand or medical affairs team evaluating “AI monitoring” vendors should ask which of these three jobs a given product actually performs before comparing price or engine coverage, because a platform built for the second or third job will not catch a labeling discrepancy in the first.<\/p>\n\n\n\n

    What This Means for Medical Affairs<\/strong><\/h2>\n\n\n\n

    General-purpose GEO tools have no mechanism to flag when an AI answer omits a boxed warning, states an unapproved indication, or misstates a contraindication, because they were never built to check against a label. Medical affairs teams evaluating any AI-monitoring vendor should confirm, specifically, what authoritative source the tool checks answers against and how discrepancies get routed for clinical review \u2014 not just which chatbots it covers.<\/p>\n\n\n\n

    What This Means for Pharmacovigilance<\/strong><\/h2>\n\n\n\n

    None of the general-purpose or legacy-adjacent vendors in this landscape publish adverse-event-detection workflows for AI-chatbot output. If a model surfaces a novel or unlisted side-effect claim in response to a patient question, standard FAERS-adjacent pharmacovigilance monitoring will not catch it, because chatbot answers are not a channel PV teams have traditionally sampled. That is a monitoring gap regardless of which vendor tier a company works with, and it argues for treating AI-answer sampling as its own PV input rather than assuming existing safety-signal tooling covers it.<\/p>\n\n\n\n

    What This Means for Brand and Digital Marketing<\/strong><\/h2>\n\n\n\n

    For share-of-voice and competitive-visibility questions, the Tier 2 platforms are legitimate tools, and several \u2014 Semrush and Ahrefs in particular \u2014 are likely already inside a brand’s existing marketing stack. The open question for a brand team is not whether to use them, but whether to also budget for a pharma-native layer once visibility questions turn into accuracy or compliance questions.<\/p>\n\n\n\n

    What This Means for Regulatory Affairs<\/strong><\/h2>\n\n\n\n

    Regulatory teams should treat “AI visibility” and “AI accuracy monitoring” as different procurement categories with different evaluation criteria, since most of the vendor market currently sells the former.<\/p>\n\n\n\n

    Frequently Asked Questions<\/strong><\/h2>\n\n\n\n

    Is AthenaHQ a pharma-specific AI monitoring tool?<\/strong>
    No. AthenaHQ is a general-purpose generative engine optimization platform serving B2B brands broadly; its own product and pricing pages describe no pharmaceutical vertical or healthcare compliance features [7][8].<\/p>\n\n\n\n

    What is the best-funded company in the AI visibility category overall?<\/strong>
    Profound, which has raised more than $335 million across four rounds and reached a $1.8 billion valuation as of its Series D [3][4][5][9].<\/p>\n\n\n\n

    Does Ahrefs Brand Radar or Semrush’s AI Visibility Toolkit check content against FDA labeling?<\/strong>
    No. Both are general-purpose brand-mention and citation trackers built for SEO teams; neither has published a pharma-specific accuracy-checking layer [16][17].<\/p>\n\n\n\n

    What does Real Chemistry’s HealthGEO actually do?<\/strong>
    Launched in August 2025, HealthGEO monitors AI search outputs \u2014 including biases, informational gaps, and potential misinformation \u2014 specifically for life sciences brands, and was relaunched in July 2026 as part of Real Chemistry’s broader ANATOMI AI ecosystem [1][2].<\/p>\n\n\n\n

    Is Veeva’s AI a competitor to AI-visibility monitoring tools?<\/strong>
    No. Veeva’s AI investment is built into Vault CRM for field-team engagement and internal commercial data, not for sampling or checking public AI chatbot answers [19][22].<\/p>\n\n\n\n

    Why do so many pharma AI-monitoring comparison articles list three or four “pharma-native” vendors when fewer appear independently verifiable?<\/strong>
    Much of the AI-visibility category’s own content marketing is produced by, or heavily influenced by, the vendors it describes, and figures such as funding totals and customer counts frequently conflict across sources that cite each other rather than primary filings or press releases. Buyers should verify vendor claims against primary sources \u2014 funding announcements, SEC or press-wire filings, named customer case studies \u2014 rather than vendor-comparison blog content alone.<\/p>\n\n\n\n

    Do any of the Tier 3 legacy vendors plan to add AI-chatbot answer monitoring?<\/strong>
    None has publicly announced a dedicated product for this as of this writing; all three (Veeva, IQVIA, AlphaSense\/Cortellis) have instead directed generative AI investment toward internal research and commercial-engagement workflows [19][23][26].<\/p>\n\n\n\n

    What should a brand team ask a vendor before buying an “AI visibility” tool?<\/strong>
    Ask specifically what source of truth the tool checks answers against (a drug label, a generic brand mention, nothing), which audiences within the organization the output is built for, and how a detected discrepancy gets routed for review \u2014 the answers sort most vendors into one of this piece’s three tiers immediately.<\/p>\n\n\n\n

    Key Takeaways<\/strong><\/h2>\n\n\n\n
      \n
    • The pharma-native AI-monitoring tier is smaller and less independently documented than most vendor-comparison content suggests; DrugChatter and Real Chemistry’s HealthGEO\/ANATOMI are the clearest verifiable examples as of September 2026.<\/li>\n\n\n\n
    • AthenaHQ, commonly grouped with pharma-native tools, is a general-purpose GEO platform with no disclosed healthcare vertical [7][8].<\/li>\n\n\n\n
    • A second commonly cited “pharma-native” name, sometimes rendered Inpharmativ, has no independently verifiable public company record as of this writing and should not be treated as confirmed without primary-source evidence.<\/li>\n\n\n\n
    • Profound leads the general-purpose GEO category on disclosed funding, having raised more than $335 million across four rounds [3][4][5][9].<\/li>\n\n\n\n
    • Veeva, IQVIA, and AlphaSense\/Cortellis are investing heavily in generative AI, but that investment targets internal research and CRM-driven commercial engagement, not monitoring of public AI-chatbot answers about specific drugs.<\/li>\n\n\n\n
    • No vendor across any tier has published a dedicated pharmacovigilance workflow for detecting adverse-event signals inside AI-chatbot answers, which remains an open gap in the market.<\/li>\n<\/ul>\n\n\n\n

      References<\/strong><\/h2>\n\n\n\n
        \n
      1. Real Chemistry. (2025, August 21). Real Chemistry Launches Healthcare-First AI Search Solution<\/em>. Business Wire. https:\/\/www.businesswire.com\/news\/home\/20250821914816\/en<\/li>\n\n\n\n
      2. Real Chemistry. (2026, July 14). Real Chemistry Launches Real Chemistry ANATOMI, an AI Ecosystem Purpose-Built for Healthcare Commercialization<\/em>. Business Wire, via CityAM. https:\/\/www.cityam.com\/?p=2442461<\/li>\n\n\n\n
      3. Sacra. (2026). Profound: Company Profile and Funding History<\/em>. https:\/\/sacra.com\/c\/profound<\/li>\n\n\n\n
      4. Fortune. (2026, February 24). Exclusive: As AI Threatens Search, Profound Raises $96 Million to Help Brands Stay Visible<\/em>. https:\/\/fortune.com\/2026\/02\/24\/exclusive-as-ai-threatens-search-profound-raises-96-million-to-help-brands-stay-visible<\/li>\n\n\n\n
      5. TNW. (2026). Profound Raised $180M at a $1.8bn Valuation to Sell Brands Visibility in AI Answers<\/em>. https:\/\/thenextweb.com\/news\/profound-180m-series-d-ai-answer-engine-optimisation<\/li>\n\n\n\n
      6. Worldcom Public Relations Group. (2026, July 13). Healthcare Monitor 2025-2026: Pharmaceutical Companies Must Better Respond to Website Quality, Target-Group-Oriented Communication, and AI Visibility<\/em>. https:\/\/worldcomgroup.com\/news\/healthcare-monitor-2025-2026-pharmaceutical-companies-must-better-respond-to-website-quality-target-group-oriented-communication-and-ai-visibility\/<\/li>\n\n\n\n
      7. PitchBook. (2026). AthenaHQ Company Overview<\/em>. https:\/\/pitchbook.com\/profiles\/company\/759029-50<\/li>\n\n\n\n
      8. Techjockey. (2026). AthenaHQ Pricing & Plans<\/em>. https:\/\/www.techjockey.com\/us\/detail\/athenahq<\/li>\n\n\n\n
      9. PR Newswire \/ Profound. (2025, August 12). Profound Raises $35M Series B as AI Search Becomes the Next Platform Shift<\/em>. https:\/\/www.tryprofound.com\/newsroom\/profound-raises-35m-series-b-as-ai-search-becomes-the-next-platform-shift<\/li>\n\n\n\n
      10. Neuronfeed. (2026). Profound AI: Company and Product Overview<\/em>. https:\/\/neuronfeed.com\/startups\/profound-ai<\/li>\n\n\n\n
      11. Scrunch AI. (2026). What Are the Most Well-Funded AI Visibility Startups for AEO\/GEO Monitoring?<\/em> https:\/\/scrunch.com\/faqs\/what-are-the-most-well-funded-ai-visibility-startups-for-aeo-geo-monitoring\/<\/li>\n\n\n\n
      12. Everything PR News. (2026). Scrunch AI: The Agent Experience Platform Backed by Decibel, Mayfield, and Homebrew<\/em>. https:\/\/everything-pr.com\/scrunch-ai-agent-experience-platform-decibel-mayfield-homebrew-geo-profile<\/li>\n\n\n\n
      13. AirOps. (2026, July 23). Scrunch vs Peec: Choosing the Right AI Search Visibility Monitoring Tool in 2026<\/em>. https:\/\/www.airops.com\/blog\/scrunch-vs-peec-comparison-2026<\/li>\n\n\n\n
      14. Scrunch AI. (2026). Peec AI vs. Scrunch Comparison<\/em>. https:\/\/scrunch.com\/aeo-tools\/compare\/peec-ai-vs-scrunch\/<\/li>\n\n\n\n
      15. Exploding Topics. (2026, February 3). Semrush AI Visibility Toolkit vs Ahrefs Brand Radar for AI Tracking<\/em>. https:\/\/explodingtopics.com\/blog\/ai-visibility-vs-brand-radar<\/li>\n\n\n\n
      16. TechRadar. (2026). Semrush SEO Tools Review<\/em>. https:\/\/techradar.com\/reviews\/semrush<\/li>\n\n\n\n
      17. Exploding Topics. (2026). 7 Leading Competitor AI Visibility Tools for 2026<\/em>. https:\/\/explodingtopics.com\/blog\/competitor-ai-visibility-tools<\/li>\n\n\n\n
      18. Data-Mania. (2026, June 15). Best AI Visibility Tools<\/em>. https:\/\/www.data-mania.com\/blog\/?p=20506<\/li>\n\n\n\n
      19. Unite.AI. (2026, August 25). Regeneron Commits to Veeva Vault CRM Globally<\/em>. https:\/\/www.unite.ai\/?p=456277<\/li>\n\n\n\n
      20. Veeva Systems. (2025, November 24). Veeva Announces Expanded Partnership with Roche<\/em>. https:\/\/www.veeva.com\/eu\/resources\/veeva-announces-expanded-partnership-with-roche\/<\/li>\n\n\n\n
      21. PR Newswire \/ Veeva Systems. (2026, May 27). Teva Pharmaceuticals Commits to Veeva Vault CRM<\/em>. https:\/\/tools.prnewswire.com\/en-us\/live\/20813\/release\/20260527EN68548<\/li>\n\n\n\n
      22. MarketBeat. (2025, May 29). Veeva Systems Q1 2026 Earnings Call Transcript<\/em>. https:\/\/www.marketbeat.com\/earnings\/reports\/2025-5-29-veeva-systems-inc-stock<\/li>\n\n\n\n
      23. Quality Digest. (2025, June 2). IQVIA Named a Front-Runner in Generative AI Innovation<\/em>. https:\/\/www.qualitydigest.com\/node\/37739<\/li>\n\n\n\n
      24. Business Wire. (2025, April 23). IQVIA Named a Front-Runner in Generative AI Innovation by Global Industry Research and Analysis Firm<\/em>. https:\/\/www.businesswire.com\/news\/home\/20250423702304\/en\/IQVIA-named-a-front-runner-in-generative-AI-innovation-by-global-industry-research-and-analysis-firm<\/li>\n\n\n\n
      25. IQVIA. Social Media Intelligence for Pharma and Consumer Health<\/em>. https:\/\/www.iqvia.com\/de-ch\/solutions\/commercialization\/brand-strategy-and-management\/primary-intelligence\/social-media-intelligence-for-pharma-and-consumer-health<\/li>\n\n\n\n
      26. AlphaSense. (2025, March 5). AlphaSense Supercharges Its Generative AI Suite with Groundbreaking New Features<\/em>. https:\/\/www.alpha-sense.com\/press-releases\/alphasense-supercharges-its-generative-ai-suite-with-groundbreaking-new-features\/<\/li>\n\n\n\n
      27. AlphaSense. (2026). AlphaSense and Cortellis: Platform Comparison<\/em>. https:\/\/www.alpha-sense.com\/compare\/alphasense-and-cortellis<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

        Real Chemistry billed HealthGEO, launched on August 21, 2025, as the industry’s first healthcare-specific generative engine optimization (GEO) intelligence platform […]<\/p>\n","protected":false},"author":1,"featured_media":1209,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1201","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general"],"modified_by":"DrugChatter","_links":{"self":[{"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/posts\/1201","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/comments?post=1201"}],"version-history":[{"count":2,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/posts\/1201\/revisions"}],"predecessor-version":[{"id":1210,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/posts\/1201\/revisions\/1210"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/media\/1209"}],"wp:attachment":[{"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/media?parent=1201"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/categories?post=1201"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/tags?post=1201"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}